Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis

Takato, Tsuyoshi; Omura, Shuji; Kikuoka, Yusuke; Suzuki, Manabu; Inaka, Yuko; Inui, Takaki; Matsuda, Masaya; Nabe, Takeshi; Kawata, Ryo

doi:10.4193/rhin19.301

Cited by 18 publications

(77 citation statements)

References 31 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full-text screening for eligibility excluded 13 studies. Thirteen studies (11 RCTs and 2 cohorts) were included in the qualitative synthesis (8,9,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) of which 10 RCTs were included in the quantitative synthesis (8,(19)(20)(21)(22)(24)(25)(26)(27)(28) . A flowchart of the study selection is illustrated in Figure 1.…”

Section: Study Selectionmentioning

confidence: 99%

“…One RCT (19) and two cohorts assessed perennial ARC patients (9,23) . Three studies assessed only patients with moderate to severe ARC (21,24,27) . Characteristics of the included studies are shown in Table 1.…”

Section: Participantsmentioning

confidence: 99%

“…Inguinal lymph nodes were the site of allergen administration in 12 studies (8,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) . One study used cervical lymph nodes (9) .…”

Section: Interventionmentioning

confidence: 99%

“…One study used cervical lymph nodes (9) . Pollen extracts were administered in 10 studies that assessed seasonal ARC patients (8,(20)(21)(22)(24)(25)(26)(27)(28)(29) . In the 3 studies of patients with perennial ARC, mixed allergen extracts (house dust mites, dog, and cat dander) (23) , house dust mite allergen extracts (9) , and a recombinant MAT-Feld1 from cat dander (19) were used in each study.…”

Section: Interventionmentioning

confidence: 99%

“…The interval between the ILIT injections was 4 weeks in 12 studies (8,9,19,(21)(22)(23)(24)(25)(26)(27)(28)(29) , and 2 weeks in 1 study (20) . Escalating doses were administered in 2 studies (19,22) and fluctuating doses in 1 study (due to adverse events) (23) .…”

Section: Interventionmentioning

confidence: 99%

See 4 more Smart Citations

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Hoang¹,

Seresirikachorn²,

Chitsuthipakorn³

et al. 2021

Rhin

View full text Add to dashboard Cite

BACKGROUND: Intralymphatic immunotherapy (ILIT) is a new route of allergen-specific immunotherapy. Data confirming its effect is restricted to a small number of studies. METHODOLOGY: A systematic review with meta-analysis was conducted. The short-term (less than 24 weeks), medium-term (24-52 weeks), and long-term (more than 52 weeks) effects of ILIT in patients with allergic rhinoconjunctivitis (ARC) were assessed. The outcomes were combined symptom and medication scores (CSMS), symptoms visual analog scale (VAS), disease-specific quality of life (QOL), specific IgG4 level, specific IgE level, and adverse events. RESULTS: Eleven randomized controlled trials and 2 cohorts (483 participants) were included. Compared with placebo, short term benefits of ILIT for seasonal ARC improved CSMS, improved VAS and increased specific IgG4 level but did not change QOL or specific IgE level. Medium-term effect improved VAS. Data on the long-term benefit of ILIT remain unavailable and require longer term follow-up studies. There were no clinical benefits of ILIT for perennial ARC. ILIT was safe and well-tolerated. CONCLUSION: ILIT showed short-term benefits for seasonal ARC. The sustained effects of ILIT were inconclusive. It was well tolerated.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Section: Participantsmentioning

confidence: 99%

“…Inguinal lymph nodes were the site of allergen administration in 12 studies (8,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) . One study used cervical lymph nodes (9) .…”

Section: Interventionmentioning

confidence: 99%

Section: Interventionmentioning

confidence: 99%

Section: Interventionmentioning

confidence: 99%

See 3 more Smart Citations

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Hoang¹,

Seresirikachorn²,

Chitsuthipakorn³

et al. 2021

Rhin

View full text Add to dashboard Cite

show abstract

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

115

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta‐analysis

Aini

Norhayati

Daud

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

Background Intralymphatic immunotherapy (ILIT) is a potential treatment option for allergic rhinitis (AR). We aimed to determine the efficacy (primary outcomes) and safety (secondary outcomes) of ILIT in treating patients with AR. Methods An electronic literature search was performed using MEDLINE and Cochrane Central Register of Controlled Trials CENTRAL (from their inception to December 2020). A random‐effects model was used to estimate the pooled prevalence with 95% confidence intervals. This study is registered with PROSPERO (CRD42019126271). Results We retrieved a total of 285 articles, of which 11 satisfied our inclusion criteria. There were 452 participants with age ranged from 15 to 58 years old. Intralymphatic immunotherapy was given in three doses with intervals of four weeks between doses in 10 trials. One trial gave three and six doses with an interval of two weeks. Both primary and secondary outcomes showed no difference between ILIT and placebo for all trials. There was no difference in the combined symptoms and medication score (SMD ‐0.51, 95% CI −1.31 to 0.28), symptoms score (SMD −0.27, 95% CI −0.91 to 0.38), medication score (SMD −6.56, 95% CI −21.48 to 8.37), rescue medication (RR 12.32, 95% CI 0.72–211.79) and the overall improvement score (MD −0.07, 95% CI −2.28 to 2.14) between ILIT and placebo. No major adverse events noted. Conclusions Intralymphatic immunotherapy possibly has a role in the treatment of AR patients. This review found it is safe but not effective, which could be contributed by the high variation amongst the trials. Future trials should involve larger numbers of participants and report standardized administration of ILIT and outcome measures.

show abstract

Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis

Cited by 18 publications

References 31 publications

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta‐analysis

Contact Info

Product

Resources

About